The genome-wide impact of trisomy 21 on DNA methylation and its

implications for hematopoiesis

SUPPLEMENTARY MATERIAL

This file includes:

- Supplementary Tables 1-4
- Supplementary Figures 1-14

 Supplementary Table 1 – Baseline characteristics of newborns with Down syndrome, with

 and without somatic GATA1 mutations.

 GATA1 mutation +ve
 GATA1 Wildtype
 P

 (N=30)
 (N=154)
 (binary)*
 P (continuous)**

	(N=30)	(N=154)	(binary)*	P (continuous)*	
	N (%)	N (%)			
Sex					
Female	17 (56.7%)	84 (54.5%)	0.38	0.46	
Male	13 (43.3%)	70 (45.5%)			
Race/ethnicity					
Latino	20 (66.7%)	76 (49.4%)	0.52	0.38	
Non-Latino white	7 (23.3%)	43 (27.9%)			
Non-Latino black	2 (6.7%)	19 (12.3%)			
Asian	1 (3.3%)	16 (10.4%)			
Blood collection age (days)					
Mean (SD)	2.53 (±1.61)	2.45 (±2.13)	0.61	0.63	
Median (range)	2.25 (0.21-6.04)	1.67 (0.17-15.25)			
Missing	1 (3.3%)	2 (1.3%)			
Gestational age (weeks)					
Mean (SD)	37.8 (±2.2)	38.3 (±2.2)	0.43	0.19	
Median (range)	38.1 (32.6-41.1)	38.3 (26.4-44.7)			
Preterm (<37 weeks, N)	10 (37.0%)	26 (16.9%)	0.033 ***		
Missing	3 (10.0%)	13 (8.4%)			
Birth weight (kg)					
Mean (SD)	2.90 (±0.56)	3.06 (±0.75)	0.71	0.57	
Median (range)	2.93 (1.61-3.98)	3.05 (0.96-8.65)			
Small-for-gestational age	6 (23.1%)	23 (16.9%)	0.42 ***		
Missing	1 (3.3%)	3 (1.9%)			

* P-values calculated using logistic regression, including GATA1 mutation as a binary variable

(presence/absence).

** P-values calculated using linear regression, including GATA1 mutation variant allele fraction (VAF) as

a continuous variable.

*** P-value calculated using two-sided Fisher's exact test.

P-values were not adjusted for multiple comparisons.

Abbreviations: kg: kilogram, SD: standard deviation.

Supplementary Table 2 – Deconvoluted blood cell proportions by Down syndrome status

and GATA1 mutation status.

	Down syndrome (DS) status				GATA1 mutation status					
Deconvoluted cell type	DS (N=196) Mean (SD); Median (range)	Non-DS (N=439) Mean (SD); Median (range)	Coefficient (SE)	Ρ	Mutation +ve (N=30) Mean (SD); Median (range)	Wildtype (N=154) Mean (SD); Median (range)	Coefficient (SE), binary*	P (binary)*	Coefficient (SE), continuous**	P (continuous)**
CD8 ⁺ T-cells	0.053 (0.032); 0.047 (0-0.190)	0.031 (0.022); 0.028 (0-0.168)	0.006 (0.003)	0.073	0.043 (0.035); 0.041 (0-0.124)	0.053 (0.030); 0.047 (0-0.190)	-0.006 (0.005)	0.24	-0.047 (0.013)	4.57E-04
CD4 ⁺ T-cells	0.119 (0.074); 0.106 (0-0.431)	0.172 (0.058); 0.165 (0.031-0.428)	-0.087 (0.005)	2.26E-53	0.152 (0.092); 0.105 (0-0.431)	0.110 (0.068); 0.095 (0-0.387)	0.041 (0.009)	2.17E-05	0.144 (0.024)	2.30E-08
B-cells	0.008 (0.011); 0.003 (0-0.051)	0.040 (0.021); 0.038 (0-0.119)	-0.031 (0.003)	3.48E-28	0.005 (0.008); 0.003 (0-0.051)	0.009 (0.012); 0.004 (0-0.051)	-0.004 (0.002)	0.13	-0.016 (0.007)	0.014
NK cells	0.026 (0.021); 0.024 (0-0.115)	0.003 (0.007); 0 (0-0.075)	0.008 (0.002)	7.97E-06	0.024 (0.021); 0.024 (0-0.115)	0.026 (0.022); 0.024 (0-0.115)	0.001 (0.004)	0.74	-0.004 (0.010)	0.67
Monocytes	0.070 (0.039); 0.070 (0-0.190)	0.083 (0.027); 0.080 (0.009-0.167)	-0.044 (0.004)	3.75E-23	0.054 (0.037); 0.070 (0-0.190)	0.072 (0.038); 0.074 (0-0.190)	-0.014 (0.006)	0.026	-0.063 (0.017)	2.82E-04
Granulocytes	0.593 (0.192); 0.648 (0-0.879)	0.655 (0.084); 0.660 (0.301-0.836)	-0.163 (0.013)	8.10E-32	0.472 (0.239); 0.649 (0-0.879)	0.614 (0.179); 0.655 (0-0.879)	-0.106 (0.031)	8.71E-04	-0.485 (0.080)	9.81E-09
nRBCs	0.116 (0.228); 0 (0-1.00)	0.005 (0.018); 0 (0-0.220)	0.299 (0.015)	4.45E-65	0.221 (0.283); 0 (0-1.00)	0.102 (0.218); 0 (0-1.00)	0.080 (0.039)	0.045	0.433 (0.104)	5.03E-05

P-values and coefficients calculated using linear regression, testing each blood cell type separately as the dependent variable, with DS status or *GATA1* mutation as the independent variable, and including plate, sex, blood collection age, gestational age, birth weight, and ten ancestry-related principal components

from EPISTRUCTURE as covariates.

* P-values and coefficients calculated in linear regression models including GATA1 mutations treated as a

binary variable (presence/absence).

** P-values and coefficients calculated in linear regression models including GATA1 mutation variant

allele fraction (VAF) as a continuous variable.

P-values were not adjusted for multiple comparisons.

Abbreviations: NK: natural killer, nRBC: nucleated red blood cell, SD: standard deviation, SE: standard error.

Supplementary Table 3 – Direction of CpG methylation changes in Down syndrome on

		Total N CpGs	Mean Beta in DS EWAS	N hypermethylated	N hypomethylated	P-value*
All CpGs	Hsa21	7,351	-0.0052	2,926 (39.8%)	4,425 (60.2%)	
	Non-Hsa21	644,421	0.00037	288,199 (44.7%)	356,222 (55.3%)	<.0001
CpG_islands	Hsa21	1,365	-0.00047	556 (40.7%)	809 (59.3%)	
	Non-Hsa21	127,257	-0.00053	44,820 (35.2%)	82,437 (64.8%)	<.0001
	Hsa21	565	-0.0077	204 (36.1%)	361 (63.9%)	
CpG_shelves	Non-Hsa21	44,465	-0.0000053	21,091 (47.4%)	23,374 (52.6%)	<.0001
	Hsa21	1,160	-0.005	434 (37.4%)	726 (62.6%)	
CpG_shores	Non-Hsa21	118,307	0.00047	56,774 (48.0%)	61,533 (52.0%)	<.0001
	Hsa21	4,261	-0.0064	1,732 (40.6%)	2,529 (59.4%)	
inter-CGI	Non-Hsa21	354,392	0.00071	165,514 (46.7%)	188,878 (53.3%)	<.0001

Hsa21 and non-Hsa21 chromosomes.

* P-values calculated using Chi-square tests.

Positions of CpGs (CpG_islands, CpG_shelves, CpG_shores, inter-CGI) were determined using the annotation database from the "IlluminaHumanMethylationEPICanno.ilm10b4.hg19" package in R. Abbreviations: CGI: CpG islands.

Supplementary Table 4 – Primer sequences used for targeted sequencing of GATA1


mutations in newborns with Down syndrome.

Assay Name	Chr	Start (bp)	End (bp)	Forward primer (incl. adapters)*	Reverse primer (incl. adapters)*	Amplicon length (bp)	GC content (%)
GATA1_1	Х	48649426	48649624	<u>ACACTGACGACATGG</u> <u>TTCTACA</u> AGGAAGAG GAGCAGGTGAAAG	TACGGTAGCAGAGAC TTGGTCTAGAGGGGA AGAAAACCCCTGATT	199	59
GATA1_2	Х	48649432	48649624	ACACTGACGACATGG <u>TTCTACA</u> aggagcaggTG AAAGGATGTG	TACGGTAGCAGAGAC TTGGTCTAGAGGGGA AGAAAACCCCTGATT	193	59
GATA1_3	Х	48649465	48649664	ACACTGACGACATGG <u>TTCTACA</u> TTCTGTGTC TGAGGACCCCTT	TACGGTAGCAGAGAC TTGGTCTGGGCAGTG GAGGAAGCTG	200	62
GATA1_4	Х	48649545	48649712	ACACTGACGACATGG TTCTACAGGACCTCAG AGCCCCTCC	TACGGTAGCAGAGAC TTGGTCTCGTCCCTG TAGTAGGCCAGT	168	64
GATA1_5	Х	48649601	48649798	ACACTGACGACATGG <u>TTCTACA</u> GAATCAGG GGTTTTCTTCCCCTC	TACGGTAGCAGAGAC TTGGTCTGATCTCCA TGGCAACCCCAAC	198	61
GATA1_ 6	Х	48650186	48650366	<u>ACACTGACGACATGG</u> <u>TTCTACA</u> TGACGTGCG CTGACCCTA	TACGGTAGCAGAGAC TTGGTCTGGTGGGAC ACACAGTTGAGG	181	59


Genomic positions correspond to human genome build hg19.

* Sequencing adapter sequences are highlighted by underlining in each primer pair.


Supplementary Figure 1 – Confirmation of trisomy 21 in newborns with Down syndrome by copy number variation (CNV) analysis of genome-wide DNA methylation data. Copy number variation across autosomal chromosomes was predicted from Illumina Infinium EPICmethylation Beadchip array data in DS (teal) and non-DS subjects (red) using the "conumee" package in R. Increased copy number (red) across chromosome 21 is clearly observed among DS (N=196) but not non-DS newborns (N=439, from which a DS outlier has already been removed). Two potential DS outliers for chromosome 21 copy number are examined in Supplementary Figure 2.



Supplementary Figure 2 – Two newborns with Down syndrome with apparent mosaic trisomy 21. Two newborns with DS according to data reported in the California Biobank Program were found to cluster among the non-DS newborns in PCA, t-SNE, and hierarchical clustering plots (Figures 1 and 2). The R package "conumee" was used to generate copy number variation (CNV) plots for all samples to check trisomy 21 status, with 20 randomly selected non-DS samples used to construct a CNV reference. Both DS newborns that clustered with non-DS newborns appear to have increased copy number on chromosome 21 relative to other chromosomes (panels b and c), but lower than the increase found in other DS samples (e.g., panel a). The boxplot in panel d shows the mean log₂ ratio on chromosome 21 calculated across 317 bins generated by conumee, for non-DS (N=439) and DS (N=196) subjects, with the two likely mosaic DS newborns highlighted at a lower than expected mean log₂ ratio. In the boxplot, the center line represents the median, the upper and lower bounds of the box represent the interquartile range (IQR, the range between the 25th and 75th percentiles), and whiskers extend to the highest and lowest values within 1.5 times the IQR.



Supplementary Figure 3 – Scatter plot displaying the variant allele frequency (VAF) of somatic *GATA1* mutations versus their effect on protein coding, in 35 variants detected among 184 newborns with Down syndrome. Somatic *GATA1* mutations with predicted functional effects (missense, frameshift insertion/deletion, splicing, nonsense) had significantly higher VAF than noncoding mutations (P=.0085, two-sided Wilcoxon rank-sum test). Two mutations – one missense and one noncoding – were detected on the same strand (red asterisks); following removal of these mutations, the difference in VAF between noncoding and functional mutations became more significant (P=.0034, two-sided Wilcoxon rank-sum test).



* Noncoding and coding variants on same strand


P **= 0.0034** following removal of these two variants, two-tailed Wilcoxon rank-sum test

Supplementary Figure 4 – Blood cell proportions deconvoluted from DNA methylation data in newborns with and without Down syndrome, and by GATA1 mutation status. Relative blood cell type proportions at birth in 196 DS (teal/blue) and 439 non-DS newborns (red) were derived from genome-wide DNA methylation array data from newborn dried bloodspots using the IDOL deconvolution algorithm. Blood cell proportions were deconvoluted for CD8⁺ T-cells, CD4⁺ T-cells, natural killer (NK) cells, B-cells, monocytes, granulocytes, and nucleated red blood cells (nRBCs). Deconvoluted blood cell proportions were visualized by boxplots generated in R. Panel a displays blood cell proportions in overall DS versus non-DS newborns, with strongly significant differences found across all comparisons in separate linear regression models, except for CD8⁺ T-cells (CD8⁺ T-cells, P=0.073; CD4⁺ T-cells, P=2.26x10⁻⁵³; NK cells, $P=7.97 \times 10^{-6}$; B-cells, $P=3.48 \times 10^{-28}$; monocytes, $P=3.75 \times 10^{-23}$; granulocytes, P=8.10x10⁻³²; nRBCs, P=4.45x10⁻⁶⁵). Panel **b** displays blood cell proportions in DS newborns stratified into GATA1 mutation-positive (blue, N=30) and wildtype (teal, N=154), and in non-DS newborns (red, N=439). Significant differences between GATA1 mutant and wildtype DS newborns were found in separate linear regression models for $CD4^+$ T-cells (P=2.17x10⁻⁵),

monocytes (P=0.026), granulocytes (P= 8.71×10^{-4}), and nRBCs (P=0.045), but not for other cell types (CD8⁺ T-cells, P=0.24; NK cells, P=0.74; B-cells, P=0.13).


In the boxplots, the center line represents the median, the upper and lower bounds of the box represent the interquartile range (IQR, the range between the 25th and 75th percentiles), and whiskers extend to the highest and lowest values within 1.5 times the IQR.

P-values were calculated by linear regression tests with each cell type as the dependent variable, and adjusting for plate, sex, age at bloodspot collection, gestational age, birthweight, and ten EPISTRUCTURE PCs. Significant P-values denoted as: *=P<.05, $**=P<5x10^{-3}$, $***=P<5x10^{-5}$.




Supplementary Figure 5 – Blood cell proportions deconvoluted from DNA methylation data in newborns with and without Down syndrome in Latinos and non-Latino whites. Relative blood cell type proportions at birth in DS (teal) and non-DS subjects (red) were derived from genome-wide DNA methylation array data from newborn dried bloodspots using the IDOL deconvolution algorithm. Blood cell proportions were deconvoluted for CD8⁺ T-cells. CD4⁺ Tcells, natural killer (NK) cells, B-cells, monocytes, granulocytes, and nucleated red blood cells (nRBCs). Deconvoluted blood cell proportions were visualized by boxplots generated in R. Panel a displays blood cell proportions in Latino DS (N=104) versus non-DS (N=253) newborns (CD8⁺ T-cells, P=0.98; CD4⁺ T-cells, P=1.46x10⁻²²; NK cells, P=2.11x10⁻³; B-cells, P=4.52x10⁻ ¹³; monocytes, $P=2.28 \times 10^{-12}$; granulocytes, $P=2.68 \times 10^{-15}$; nRBCs, $P=4.40 \times 10^{-31}$). Panel **b** displays proportions in non-Latino white DS (N=54) versus non-DS (N=124) newborns (CD8⁺ T-cells, P=0.034; CD4⁺ T-cells, P=7.26x10⁻²⁵; NK cells, P=4.29x10⁻³; B-cells, P=3.28x10⁻⁷; monocytes, $P=1.33 \times 10^{-6}$; granulocytes, $P=4.93 \times 10^{-12}$; nRBCs, $P=5.05 \times 10^{-30}$). In both analyses, strongly significant differences were found across all comparisons in separate linear regression models, except for CD8⁺ T-cells. In the boxplots, the center line represents the median, the upper and lower bounds of the box represent the interquartile range (IQR, the range between the 25th and 75th percentiles), and whiskers extend to the highest and lowest values within 1.5 times the IQR.

P-values were calculated by linear regression tests with each cell type as the dependent variable, and adjusting for plate, sex, age at bloodspot collection, gestational age, birthweight, and ten EPISTRUCTURE PCs. Significant P-values denoted as: *=P<.05, $**=P<5x10^{-3}$, $***=P<5x10^{-5}$.




Supplementary Figure 6 – Scatter plot displaying the proportion of nucleated red blood cells (nRBC) versus *GATA1* mutation variant allele frequency (VAF) in 184 newborns with Down syndrome. nRBC proportions were deconvoluted from DNA methylation array data using the IDOL algorithm. Targeted sequencing revealed 30 of 184 DS newborns harbored somatic *GATA1* mutations. Linear regression was performed to assess the relationship between *GATA1* mutation VAF and nRBC proportions, adjusting for plate, sex, age at bloodspot collection, gestational age, birthweight, and ten EPISTRUCTURE PCs, and found significant positive association (P= 5.0×10^{-5}).



Supplementary Figure 7 – Significant hypermethylation in Down syndrome at *RUNX1* on chromosome 21, which is specific to the P2 promoter.

a: Manhattan plot displaying the $-\log_{10}(P)$ -values of CpGs on chromosome 21, derived from the multi-ethnic EWAS of DS. Points above zero correspond to CpGs that were hypermethylated in DS versus non-DS newborns, whereas points below zero correspond to hypomethylated CpGs in DS. P-values were derived from linear regression tests adjusting for sex, plate, the first ten EPISTRUCTURE PCs to control for genetic ancestry, and the first ten ReFACTor PCs to control for cell mixture. The dotted lines correspond to the threshold for epigenome-wide significance (P=7.67x10⁻⁸) after Bonferroni correction for multiple testing, based on 651,773 CpGs. The strong association peak at *RUNX1* is highlighted.


b: Plot displaying the DS EWAS results for 122 CpG probes across the *RUNX1* gene (chr21: 36163427-36423674, hg19). Chromosome 21 positions of the proximal P2 (chr21:36260988-36261987) and distal P1 promoters of *RUNX1* were retrieved using the UCSC Genome Browser Table Browser, for the transcription start site of each relevant transcript minus 1,000bp. Significantly hypermethylated DS-associated CpGs were identified at the P2 promoter, but not the P1 promoter region. Two DS-associated, hypermethylated DMRs (DMR1, DMR2) were detected at the P2 promoter, and one hypomethylated DMR (DMR3) was identified at the P1 promoter.



36150000 36175000 36200000 36225000 36250000 36275000 36300000 36325000 36350000 36375000 36400000 36425000 36450000


Chromosome 21 position

Supplementary Figure 8 – Enrichment of Down syndrome-associated CpGs in epigenomic features by hyper- and hypomethylation status. Bar charts representing the proportions of epigenome-wide significant and non-significant CpGs that overlapped genomic and epigenomic features including: promoters, exons, introns, intergenic regions, CpG islands, shores, and shelves. Hypomethylated CpGs (green) were significantly underrepresented at promoter regions (P= $6.14x10^{-4}$) and at CpG islands (P= $3.59x10^{-10}$) but significantly enriched in intergenic regions (P= $1.56x10^{-6}$) compared to non-significant CpGs (chi-square test). Significant P-values denoted as: **=P< $5x10^{-3}$, ***=P< $5x10^{-5}$.



Genomic location

Supplementary Figure 9 – Proportion of Down syndrome-associated differentially methylated regions (DMRs) across autosomal chromosomes. DMRs were identified on all chromosomes, with a particularly high proportion (11.2%) on chromosome 21, as well as chromosomes 1, 6, 11, 12, 16, 17, and 19.




Proportion of DMRs per chromosome

Chromosomes

Supplementary Figure 10 – Expression of FLI1 protein transcript variants across blood cell types in the BLUEPRINT Blood Atlas. Plots displaying *FLI1* transcript variant expression across 27 blood cell types, calculated as mean expression in each cell type (**a**) and as the expression in each cell type relative to total expression across all cell types (**b**). Data were downloaded from the BLUEPRINT Consortium Blood Atlas

(https://blueprint.haem.cam.ac.uk/bloodatlas/), which includes expression data from whole transcriptome RNA sequencing in 27 cell types from cord blood (Cb) and adult peripheral venous blood (Vb) (https://blueprint.haem.cam.ac.uk/bloodatlas/samples.html), and are displayed for the 4 main protein coding *FLI1* transcripts. The DS-associated DMR at *FLI1* overlapped the promoter for transcript variant 4, which was mainly expressed in cord blood megakaryocyte cells, a pattern not seen in other transcript variants.



Vb: adult venous blood; Cb: cord blood.

MSC:mesenchymal stem cell of the bone marrow; BOEC:blood outgrowth endothelial cells; HUVEC (R):human umbilical vein endothelial cells (resting); HUVEC (P):human umbilical vein endothelial cells (proliferating); PLT:platelets; MK:CD34-negative, CD41-positive, CD42-positive megakaryocyte cell; EB:erythroblast; EOS:eosinophil; BAS:basophil; NEU:mature neutrophil; MONO:CD14-positive, CD-16 negative classical monocyte; M0:macrophage; M1:inflammatory macrophage; M2:alternatively activated macrophage; DC:conventional dendritic cell; CD4 naive:CD4-positive, alpha-beta T cell; CD4 CM:central memory CD4-positive, alpha-beta T cell; CD4 EM:effector memory CD4-positive, alpha-beta T cell; CD8 naive:CD8-positive, alpha-beta T cell; CD8 TDEM:terminally differentiated effector memory CD8-positive, alpha-beta T cell; T reg:regulatory T cell; B naive:CD38-negative naive B cell; B M:memory B cell; B CS:class switched memory B cell; NK:cytotoxic CD56-dim natural killer cell.

Supplementary Figure 11 – Down syndrome-associated DMRs with large differences in

DNA methylation. DS-associated DMRs overlapping regulatory regions in *CPT1B* (**a**), *PRDM8* (**b**), *ASB3* (**c**), and *CMYA5* (**d**). These DMRs all include at least 10 CpG probes with a mean beta difference >0.10.

Figure S11a

CPT1B DMR




Figure S11b

PRDM8 DMR




Figure S11c

ASB3 DMR








Figure S11d

CMYA5 DMR




Supplementary Figure 12 – *RUNX1* promoter DMR mean DNA methylation levels in newborns with and without Down syndrome, and by *GATA1* mutation status. Boxplots displaying the mean DNA methylation beta values across 11 CpGs in a *RUNX1* promoter DMR: (a) among non-DS newborns (N=439) versus DS newborns (N=196), and (b) among *GATA1* mutation-positive DS newborns (N=30) versus mutation wildtype (wt) newborns (N=154). In the boxplots, the center line represents the median, the upper and lower bounds of the box represent the interquartile range (IQR, the range between the 25th and 75th percentiles), and whiskers extend to the highest and lowest values within 1.5 times the IQR.



Mean DNA methylation levels at *RUNX1* promoter DMR by DS status and *GATA1* mutation status

Supplementary Figure 13 – *FLI1* promoter DMR mean DNA methylation levels in newborns with and without Down syndrome, and by *GATA1* mutation status. Boxplots displaying the mean DNA methylation beta values across 19 CpGs in a *FLI1* promoter DMR: (a) among non-DS newborns (N=439) versus DS newborns (N=196), and (b) among *GATA1* mutation-positive DS newborns (N=30) versus mutation wildtype (wt) newborns (N=154). In the boxplots, the center line represents the median, the upper and lower bounds of the box represent the interquartile range (IQR, the range between the 25th and 75th percentiles), and whiskers extend to the highest and lowest values within 1.5 times the IQR.

Mean DNA methylation levels at *FLI1* promoter DMR by DS status and *GATA1* mutation status



Supplementary Figure 14 – Correlation between differential methylation at Down syndrome-associated DMRs in gene body, intergenic regions, and on chromosome 21 in newborn dried bloodspots and differential gene expression in fetal liver CD34+ cells in DS and non-DS samples. Bar charts displaying the number of hypomethylated and hypermethylated DS-associated DMRs along with the direction of differential expression of corresponding genes in RNA-sequencing of DS (N=3) versus non-DS (N=3) FL CD34+ cells. Panel a displays results for DMRs on all chromosomes overlapping the gene body. Panel b displays results for DMRs on all chromosome overlapping intergenic regions, for which differential expression was compared for the nearest gene as classified by DMRcate. Results are also displayed for DMRs only on chromosome 21 and overlapping promoters/enhancers (c), gene body (d), and intergenic regions (e). P-values were calculated by two-sided Fisher's exact test.

